TIDMGSK
RNS Number : 1549F
GlaxoSmithKline PLC
12 November 2020
Issued: GlaxoSmithKline plc ("GSK"), 12 November 2020, London,
UK and Quebec City, Canada
Medicago and GSK announce start of Phase 2/3 clinical trials of
adjuvanted COVID-19 vaccine candidate
-- The COVID-19 vaccine candidate will contain GSK's pandemic adjuvant
-- Phase 3 part of clinical trial to enrol over 30,000 volunteers worldwide
Medicago, a biopharmaceutical company headquartered in Quebec
City, and GSK are pleased to announce the start of Phase 2/3
clinical trials of its plant-derived vaccine candidate for COVID-19
to evaluate its efficacy, safety, and immunogenicity. Based on the
positive Phase 1 results, Medicago has decided to launch the Phase
2/3 clinical trial with GSK's pandemic adjuvant.
Nathalie Landry, Executive Vice President, Scientific and
Medical Affairs at Medicago, said: "Our Phase 1 results of the
adjuvanted vaccine candidate were very encouraging and fully
support further clinical evaluation."
Thomas Breuer, Chief Medical Officer GSK Vaccines said: "This is
the first of several GSK COVID-19 vaccine candidate collaborations
to start Phase 2/3 clinical testing and an important step forward
in our contribution to the global fight against the pandemic. We
are delighted with the very promising Phase 1 results of Medicago's
COVID-19 vaccine candidate in combination with GSK's pandemic
adjuvant. Proven dose sparing and a high immune response due to
GSK's adjuvant make us confident of delivering an efficacious
vaccine with an acceptable safety profile in collaboration with
Medicago."
The Coronavirus-Like Particle COVID-19 vaccine candidate (CoVLP)
is composed of recombinant spike (S) glycoprotein expressed as
virus-like particles (VLPs).
The study is a multi-portion design to confirm that the chosen
formulation and dosing regimen of CoVLP (two doses of 3.75 ug CoVLP
combined with GSK's pandemic adjuvant given 21 days apart) has an
acceptable immunogenicity and safety profile in healthy adults
18-64 years of age and in elderly subjects aged 65 and over.
The Phase 2 trial part is a randomized, observer-blind,
placebo-controlled study to evaluate the safety and immunogenicity
of the adjuvanted recombinant COVID-19 plant-derived vaccine
candidate in subjects aged 18 and above. It will be conducted in
multiple sites in Canada and, upon FDA allowance, in the United
States and in a population composed of healthy adults (18-64y) and
elderly adults (over 65y). Each age group will have over 300
subjects randomized 5:1 to receive the adjuvanted CoVLP vaccine
candidate: placebo and with 2:1 stratification in older adults
(65-74 and >=75). All subjects will be followed for a period of
12 months after the last vaccination for the assessment of safety
and durability of the immune responses to the vaccine
candidate.
The Phase 3 part of the study will start before the end of 2020
and is an event-driven, randomized, observer-blinded,
placebo-controlled design that will evaluate the efficacy and
safety of the CoVLP formulation, compared to placebo, in over
30,000 subjects in North America, Latin America and/or Europe and
within the same population, or - alternatively - amongst a broader
one pending approval by regulatory authorities.
About Medicago
Medicago is a biopharmaceutical company and pioneer in
plant-derived therapeutics. Founded in 1999 with the belief that
innovative approaches and rigorous research would bring new
solutions in healthcare.
Our mission is to improve global health outcomes by leveraging
innovative plant-based technologies for rapid responses to emerging
global healthcare challenges. Medicago is committed to advancing
therapeutics against life-threatening diseases worldwide. Our team
includes over 450 scientific experts and employees in Canada and
the United States and academic affiliations in Europe and South
Africa.
Medicago has previously demonstrated its capability to be a
first responder in a flu pandemic. In 2009, the company produced a
research-grade vaccine candidate against H1N1 in just 19 days. In
2012, Medicago manufactured 10 million doses of a monovalent
influenza vaccine candidate within one month for the Defense
Advanced Research Projects Agency (DARPA), part of the U.S.
Department of Defense. In 2015, Medicago also demonstrated in
principle that it could rapidly produce an anti-Ebola monoclonal
antibody cocktail for the Biomedical Advanced Research and
Development Authority (BARDA), part of the U.S. Department of
Health and Human Services.
For more information: www.medicago.com
To learn more about our plant-based technology: Video / Website
About GSK and its commitment to tackling COVID-19
GSK is a science-led global healthcare company with a special
purpose: to help people do more, feel better, live longer. For
further information please visit www.gsk.com/about-us .
GSK is collaborating with companies and research groups across
the world working on promising COVID-19 vaccine candidates through
the use of our innovative vaccine adjuvant technology. The use of
an adjuvant is of particular importance in a pandemic situation
since it may reduce the amount of vaccine protein required per
dose, allowing more vaccine doses to be produced and therefore
contributing to protecting more people. GSK does not expect to
profit from COVID-19 vaccines during the pandemic phase, and will
invest any short-term profit in coronavirus related research and
long-term pandemic preparedness, either through GSK internal
investments or with external partners.
GSK enquiries:
Media enquiries: Simon Steel +44 (0) 20 8047 (London)
5502
Simon Moore +44 (0) 20 8047 (London)
5502
Kristen Neese +1 804 217 8147 (Philadelphia)
Kathleen Quinn +1 202 603 5003 (Washington
DC)
Analyst/Investor enquiries: Sarah Elton-Farr +44 (0) 20 8047 (London)
5194
Sonya Ghobrial +44 (0) 7392 (Consumer)
784784
James Dodwell +44 (0) 20 8047 (London)
2406
Jeff McLaughlin +1 215 751 7002 (Philadelphia)
Frannie DeFranco +1 215 751 4855 (Philadelphia)
Medicago Media contacts
(English):
Alissa Von Bargen
+1-647-234-5975
Alissa.VonBargen@gcicanada.com
Medicago Media contact
(French):
Marie-Pier Côté
+ 1-418-999-4847
mpcote@tactconseil.ca
GSK Cautionary Statement Regarding Forward-Looking
Statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
"Risk Factors" in the company's Annual Report on Form 20-F for 2019
and as set out in GSK's "Principal risks and uncertainties" section
of the Q3 Results and any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFFAFEEESSEDF
(END) Dow Jones Newswires
November 12, 2020 08:00 ET (13:00 GMT)
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Mar 2023 a Mar 2024